These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8015637)

  • 1. Endothelin in chronic renal failure.
    Takahashi K; Totsune K; Mouri T
    Nephron; 1994; 66(4):373-9. PubMed ID: 8015637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of recombinant human erythropoietin therapy on plasma endothelin-1 levels during hemodialysis.
    Stefanidis I; Mertens PR; Wurth P; Bach R; Makropoulos W; Mann H; Heintz B
    Int J Artif Organs; 2001 Jun; 24(6):367-73. PubMed ID: 11482502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma concentrations of immunoreactive-endothelin in patients with chronic renal failure treated with recombinant human erythropoietin.
    Takahashi K; Totsune K; Imai Y; Sone M; Nozuki M; Murakami O; Sekino H; Mouri T
    Clin Sci (Lond); 1993 Jan; 84(1):47-50. PubMed ID: 8382133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure.
    Hand MF; Haynes WG; Johnstone HA; Anderton JL; Webb DJ
    Kidney Int; 1995 Sep; 48(3):806-13. PubMed ID: 7474668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin in patients with chronic renal failure.
    Nĕmecek K; Bártová V; Jáchymová M; Horký K
    Ren Fail; 1995 Sep; 17(5):559-63. PubMed ID: 8570868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients.
    Kang DH; Yoon KI; Han DS
    Nephrol Dial Transplant; 1998 Nov; 13(11):2877-83. PubMed ID: 9829494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis.
    Lai KN; Lui SF; Leung JC; Law E; Nicholls MG
    Nephron; 1991; 57(4):394-400. PubMed ID: 1828543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
    Holley JL; Nolan TA; Piraino B
    Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma endothelin in haemodialysis patients treated with recombinant human erythropoietin.
    Brunet P; Lorec AM; Leonetti F; Roubicek C; Jaber K; Roux F; Berland Y
    Nephrol Dial Transplant; 1994; 9(6):650-4. PubMed ID: 7970091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular hemodynamic effects of correction of anemia of chronic renal failure with recombinant-human erythropoietin.
    Schwartz AB; Prior JE; Mintz GS; Kim KE; Kahn SB
    Transplant Proc; 1991 Apr; 23(2):1827-30. PubMed ID: 2053168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of endothelin in cardiovascular disease.
    Agapitov AV; Haynes WG
    J Renin Angiotensin Aldosterone Syst; 2002 Mar; 3(1):1-15. PubMed ID: 11984741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
    Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
    Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the alpha adrenergic system and increase in blood pressure with recombinant human erythropoietin (rHuEpo) therapy for renal anemia.
    Müller R; Steffen HM; Brunner R; Saric J; Pollok M; Baldamus CA; Kaufmann W
    Clin Invest Med; 1991 Dec; 14(6):614-22. PubMed ID: 1665406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of intrarenal endothelin in the generation and maintenance of hypertension.
    Markewitz BA; Kohan DE
    Miner Electrolyte Metab; 1995; 21(4-5):342-52. PubMed ID: 7565483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin and the anemia of chronic diseases.
    De Marchi S; Pirisi M; Ferraccioli GF
    Clin Exp Rheumatol; 1993; 11(4):429-44. PubMed ID: 8403591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of renal anemia in children and adolescents with recombinant human erythropoietin (rHuEPO).
    Campos A; Garin EH
    Clin Pediatr (Phila); 1992 Feb; 31(2):94-9. PubMed ID: 1544282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of anemia using recombinant human erythropoietin in patients on chronic hemodialysis.
    Cotton SL; Holechek MJ
    ANNA J; 1989 Dec; 16(7):463-8. PubMed ID: 2604448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human erythropoietin (rHuEPO) in the treatment of anaemia of chronic renal failure.
    Desai JD; Shah BV
    J Assoc Physicians India; 1991 Jun; 39(6):483-5. PubMed ID: 1938855
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.